Standard of care for astrocytic gliomas

• Nagane Motoo

  Department of Neurosurgery Kyorin University Faculty of Medicine

Bibliographic Information

Other Title

• 星細胞腫系神経膠腫の標準治療

Abstract

Gliomas represent the most frequent malignant neoplasms that arise in the central nervous system. Astrocytic tumors comprise 78% of all gliomas and their histological grade (I – IV) is defined according to the current WHO classification. Although the prognosis of grade IV glioblastoma (GBM), the most malignant form of gliomas, is still detrimental, there have been progress in the management of these tumors since a number of confirming phase III clinical trials have been conducted in the last decade to provide with standard of care(SOC) therapies. Here I will focus on such pivotal trials for astrocytic tumors and discuss issues that need to be solved in the future studies.

Journal

• Progress in Neuro-Oncology

  Progress in Neuro-Oncology 22 (3), 8-20, 2015

  Kinki Brain Tumor Pathology Conference

Keywords

• Glioma
• astrocytic tumors
• standard of care
• molecular marker
• clinical trial

Details

• CRID: 1390001205506028544
• NII Article ID: 130005117930
• DOI: 10.11452/neurooncology.22.3_8
• ISSN: 21870551
• ISSN: 18800742
• Web Site: https://search.jamas.or.jp/link/ui/2016267933
• Text Lang: en
• Data Source:
  • JaLC
  • CiNii Articles
  • KAKEN
• Abstract License Flag: Disallowed